<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142050</url>
  </required_header>
  <id_info>
    <org_study_id>Cellonis-CR-2.3</org_study_id>
    <nct_id>NCT01142050</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellonis Biotechnology Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellonis Biotechnology Co. Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety in the treatment of Insulin
      Resistance of Type 2 Diabetes Mellitus with Bone Marrow Mesenchymal Stem Cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the feasibility and safety of transplantation treatment using umbilical cord
           mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing insulin
           injection treatments.

        -  To assess efficacy of transplantation treatment using umbilical cord mesenchymal stem
           cells in patients with type 2 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;</measure>
    <time_frame>one year</time_frame>
    <description>Insulin resistance index indicated by ITT change compared with baseline.
Rate of reducing exogenous insulin requirement and OGLD dosage compared with baseline.
Hemoglobin A1c.
Fast blood glucose (FBG) and Postmeal blood glucose (PBG).
C-peptide levels.
Serum Insulin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event frequency and severity</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Free will taking part in the study and ability to provide written informed consent;

          2. Type 2 diabetes mellitus (as guideline WHO, 1999);

          3. Age 18-75 years old，Male/Female;

          4. 19≤Body mass index (BMI)≤30㎏/㎡;

          5. Fast blood glucose (FBG)≥7.0 mmol/L, and HbAc1≥7％;

          6. Intravenous insulin tolerance test（ITT）indicate patient being insulin resistance;

          7. Not pregnant or nursing;

          8. Negative pregnancy test;

          9. Fertile patients will use effective contraception.

        Exclusion Criteria:

          1. Severe concurrent medical condition (e.g., serious heart disease, lung disease, or
             hematopoietic dysfunction, or liver dysfunction, or kidney dysfunction);

          2. Active infection requiring treatment;

          3. Unexplained febrile illness;

          4. Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Armed Police General Hospital, P.R. China</name>
      <address>
        <city>Beijing</city>
        <zip>100085</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shi X Y, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cellonis Biotechnology Co. Ltd.</name_title>
    <organization>others</organization>
  </responsible_party>
  <keyword>stem cells;</keyword>
  <keyword>diabetes mellitus;</keyword>
  <keyword>treatment.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

